TY - JOUR
T1 - Economic considerations of macular edema therapies
AU - Smiddy, William E.
N1 - Funding Information:
Supported by National Institutes of Health center Grant P30-EY014801 , an unrestricted grant to Bascom Palmer Eye Institute from Research to Prevent Blindness .
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/9
Y1 - 2011/9
N2 - Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
AB - Purpose To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Design A model of resource use, outcomes, and cost-effectiveness and utility. Participants None. Methods Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. Main Outcome Measures Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). Results The lines saved for DME (0.262.02), BRVO (0.744.92), and CRVO (1.23.75) yielded calculations of costs/line of saved VA for DME ($1329$11,609), BRVO ($494$13,039), and CRVO ($704$7611); costs/line-year for DME ($60$561), BRVO ($25$754), and CRVO ($45$473); and costs/QALY ($824 to $25,566). Conclusions Relative costs and benefits should be considered in perspective when applying and developing treatment strategies. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
UR - http://www.scopus.com/inward/record.url?scp=80052445162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052445162&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2010.12.034
DO - 10.1016/j.ophtha.2010.12.034
M3 - Article
C2 - 21507488
AN - SCOPUS:80052445162
VL - 118
SP - 1827
EP - 1833
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 9
ER -